



Foundation Medicine, Inc.  
Investor Relations Department  
150 Second Street  
Cambridge, MA 02141  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: FMI

Last Trade:	42.05
Trade Time:	2:06 PM ET June 22, 2017
Change:	0.70  (+1.693%)
Day Range	41.05 - 42.45
52-Week Range	16.95 - 43.15
Volume	85,609

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Foundation Medicine is a commercial-stage company focused on fundamentally changing the way patients with cancer are treated. Our proprietary molecular information platform generates actionable genomic information about a patient's individual cancer, enabling physicians to optimize treatments in clinical practice and enabling biopharmaceutical companies to develop targeted oncology therapies more effectively. The Company's first clinical product, [FoundationOne™](#), is the only commercially available comprehensive molecular infor... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

June 8, 2017

[ASCO and Foundation Medicine Announce Collaboration to Help Research Sites Identify Potential Participants for the Targeted Agent and Profiling Utilization \(TAPUR\) Study](#)

June 7, 2017

[Foundation Medicine to Identify Patients Eligible for National Cancer Institute's NCI-MATCH \(Molecular Analysis for Therapy Choice\) Study](#)

June 5, 2017

[Foundation Medicine to Present at Upcoming Investor Conferences](#)

May 18, 2017

[Foundation Medicine and Its Collaborators to Present New Data at ASCO 2017 Supporting the Integration of Comprehensive Genomic Profiling \(CGP\) in Personalized Clinical Care in Oncology](#)

May 9, 2017

[Foundation Medicine Announces 2017 First Quarter Results and Recent Highlights](#)

## Upcoming Events [\[ View all \]](#)

Sep 8–12, 2017

[ESMO 2017 Conference](#)

Oct 8–11, 2017

[CAP – College of American Pathologists](#)

## Financials [\[ View all \]](#)

[First Quarter Financial Results](#)

March 3, 2017

[Annual Report \(10-K\)](#)

April 28, 2017

[Proxy Statement \(DEF 14A\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)

November 2, 2016

[Quarterly Report \(10-Q\)](#)

August 3, 2016

[Quarterly Report \(10-Q\)](#)